newsfilter
← Latest News
GlobeNewswire·

Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

SOUTH SAN FRANCISCO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recurrence (ROR) test has received coverage